Adolf E. Schindler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adolf E. Schindler has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Carlo Campagnoli
Ospedale Ginecologico St. Anna, Corso Spezia 60, 10126 Torino, Italy
2 shared publicationsJohannes Huber
Abt. für Gynäkologische Endokrinologie, AKH Wien, Währingergürtel 18-20, 1090 Wien, Austria
2 shared publicationsRené Druckmann
Ameno-Menopause-Center, 12, Rue de France, 06000 Nice, France
2 shared publicationsB. Gerber
University of Rostock
1 shared publicationC. Oberhoff
University of Essen
1 shared publicationJorge R Pasqualini
1 shared publication
Latest Publications
- 1 January 2006
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 22 (3) , 151-154
Climacteric symptoms and hormones
Climacteric symptoms are so closely associated with the menopause to be practically considered its hallmark. However, symptoms can already appear before the onset of menopause. The frequency, extent and intensity of symptoms are dependent on social factors, body composition, race and geographical region. In about 20–25% of menopausal women they do not occur at all. These symptoms are most prominent in women who are suddenly deprived of their endogenous estrogen secretion, for instance by bilateral ovariectomy, particularly in younger women. Climacteric symptoms can to be subdivided into five categories: menstrual bleeding disorders; vegetative symptoms; psychosomatic symptoms; somatotrophic changes; and metabolic changes. For prevention and treatment of the various symptoms, estrogen/progestogen replacement therapy (HRT) or estrogen replacement therapy (ERT) in individualized dosages and various forms of applications are the most cost-effective modalities in order to control menopausal symptoms and restore organic function, or prevent all of this and improve women's quality of life. Recent publications indicate that gene polymorphisms may be associated with severe and persistent climacteric symptoms. This is also true for current and ever cigarette smokers.
- 1 January 2006
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 22 (3) , 151-154
Climacteric symptoms and hormones
Climacteric symptoms are so closely associated with the menopause to be practically considered its hallmark. However, symptoms can already appear before the onset of menopause. The frequency, extent and intensity of symptoms are dependent on social factors, body composition, race and geographical region. In about 20–25% of menopausal women they do not occur at all. These symptoms are most prominent in women who are suddenly deprived of their endogenous estrogen secretion, for instance by bilateral ovariectomy, particularly in younger women. Climacteric symptoms can to be subdivided into five categories: menstrual bleeding disorders; vegetative symptoms; psychosomatic symptoms; somatotrophic changes; and metabolic changes. For prevention and treatment of the various symptoms, estrogen/progestogen replacement therapy (HRT) or estrogen replacement therapy (ERT) in individualized dosages and various forms of applications are the most cost-effective modalities in order to control menopausal symptoms and restore organic function, or prevent all of this and improve women's quality of life. Recent publications indicate that gene polymorphisms may be associated with severe and persistent climacteric symptoms. This is also true for current and ever cigarette smokers.
- 1 December 2005
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 97 (5) , 386-388
Endocrinology of pregnancy: Consequences for the diagnosis and treatment of pregnancy disorders
- 1 December 2005
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 97 (5) , 386-388
Endocrinology of pregnancy: Consequences for the diagnosis and treatment of pregnancy disorders
- 1 December 2005
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 97 (5) , 435-438
Role of progestogens for the prevention of premature birth
- 1 December 2005
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 97 (5) , 435-438
Role of progestogens for the prevention of premature birth
- 29 November 2005
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- p. 1
The safety of synthetic paclitaxel by intralesional delivery with OncoGel™ into skin breast cancer metastases: method and results of a clinical pilot trial
Ahead of Print article withdrawn by publisher
- 29 November 2005
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- p. 1
The safety of synthetic paclitaxel by intralesional delivery with OncoGel™ into skin breast cancer metastases: method and results of a clinical pilot trial
Ahead of Print article withdrawn by publisher
- 27 October 2004
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 208 (5) , 165-169
Prävention der Frühgeburtlichkeit durch Gestagene
Frühgeburtlichkeit mit den damit verbundenen Kurzzeit- und Langzeit-Konsequenzen stellt ein ernsthaftes Problem im Hinblick auf Morbidität, körperliche Beeinträchtigung und Mortalität der Neugeborenen und Kosten für die Gesellschaft dar. Der Anteil der Frühgeburtlichkeit persistiert und nach den neuesten nationalen und internationalen Daten besteht sogar ein Trend zur Zunahme. Deshalb sollte man neben Screeningprogrammen für die Erkennung vaginaler Infektionen die Suche nach zusätzlichen therapeutischen Konzepten vornehmen. Aufgrund vorangehender Publikationen und der gegenwärtigen Datenlage sollten Progesteron vaginal und 17α-Hydroxyprogesteronkaproat als mögliche Therapieoptionen ab dem 2. Trimenon bei Risiko einer Frühgeburt als Prävention in Erwägung gezogen werden. Preterm delivery with its short-term and long-term sequealae constitutes a serious problem in terms of morbidity, disability and mortality of the newborn and cost to the society. The incidence of premature deliveries persists and according to the latest national and international reports a tendency for an increase has been observed. Therefore, besides screening programmes for the detection of vaginal infections one has to look for additional therapeutic concepts. According to previous data and recent publications, progesterone vaginally and 17α-hydroxyprogesterone caproate intramuscularely should be considered as possible treatment options for the prevention of preterm delivery in high-risk women, with therapy starting in the second trimester.
- 27 October 2004
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 208 (5) , 165-169
Prävention der Frühgeburtlichkeit durch Gestagene
Frühgeburtlichkeit mit den damit verbundenen Kurzzeit- und Langzeit-Konsequenzen stellt ein ernsthaftes Problem im Hinblick auf Morbidität, körperliche Beeinträchtigung und Mortalität der Neugeborenen und Kosten für die Gesellschaft dar. Der Anteil der Frühgeburtlichkeit persistiert und nach den neuesten nationalen und internationalen Daten besteht sogar ein Trend zur Zunahme. Deshalb sollte man neben Screeningprogrammen für die Erkennung vaginaler Infektionen die Suche nach zusätzlichen therapeutischen Konzepten vornehmen. Aufgrund vorangehender Publikationen und der gegenwärtigen Datenlage sollten Progesteron vaginal und 17α-Hydroxyprogesteronkaproat als mögliche Therapieoptionen ab dem 2. Trimenon bei Risiko einer Frühgeburt als Prävention in Erwägung gezogen werden. Preterm delivery with its short-term and long-term sequealae constitutes a serious problem in terms of morbidity, disability and mortality of the newborn and cost to the society. The incidence of premature deliveries persists and according to the latest national and international reports a tendency for an increase has been observed. Therefore, besides screening programmes for the detection of vaginal infections one has to look for additional therapeutic concepts. According to previous data and recent publications, progesterone vaginally and 17α-hydroxyprogesterone caproate intramuscularely should be considered as possible treatment options for the prevention of preterm delivery in high-risk women, with therapy starting in the second trimester.
- 1 October 2004
- Vol. 56 (5) , 419-35
Pathophysiology, diagnosis and treatment of endometriosis.
Endometriosis is generally a benign condition. However, there is a tendency towards progression and in part deep infiltrating processes occur, which can lead to obstruction and even silent loss of organ function such as kidney failure. Hereditary, genetic and immunological peculiarities have been found. Important are symptoms such as pain and infertility, which burden the life of the women involved. In spite of extensive research in the past the pathogenesis and epidemiology of the disease are not definitely clarified as yet. The estimated prevalence of endometriosis ranges between 10% and even more than 50% depending on the underlying problems of the women studied. Besides the main location of the disease within the pelvis also extra pelvic locations have been found (lung, lymph nodes, scars). The diagnosis should be established by histological verification. The main therapeutic modalities consist of surgery and medical treatment or combinations, which need to be individually adjusted, because of the high risk of recurrence and progression of the disease. The aim should be early detection and treatment as complete as possible, since symptom relief, resolution or prevention of infertility and decrease of recurrences are at their best under these circumstances.
- 1 October 2004
- Vol. 56 (5) , 419-35
Pathophysiology, diagnosis and treatment of endometriosis.
Endometriosis is generally a benign condition. However, there is a tendency towards progression and in part deep infiltrating processes occur, which can lead to obstruction and even silent loss of organ function such as kidney failure. Hereditary, genetic and immunological peculiarities have been found. Important are symptoms such as pain and infertility, which burden the life of the women involved. In spite of extensive research in the past the pathogenesis and epidemiology of the disease are not definitely clarified as yet. The estimated prevalence of endometriosis ranges between 10% and even more than 50% depending on the underlying problems of the women studied. Besides the main location of the disease within the pelvis also extra pelvic locations have been found (lung, lymph nodes, scars). The diagnosis should be established by histological verification. The main therapeutic modalities consist of surgery and medical treatment or combinations, which need to be individually adjusted, because of the high risk of recurrence and progression of the disease. The aim should be early detection and treatment as complete as possible, since symptom relief, resolution or prevention of infertility and decrease of recurrences are at their best under these circumstances.
- 1 February 2004
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 112 (2) , 136-141
Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception
- 1 February 2004
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 112 (2) , 136-141
Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception